Improving follow-up care for lung cancer survivors
Toward an Integrated Approach to Assessing and Addressing Follow-Up Care Needs That Will Facilitate Care Transitions for Cancer Survivors: A Pilot Study
This study is testing a new support program for lung cancer survivors to see if working with a navigator to create a personalized care plan helps them get better follow-up care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT06654245 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a shared response plan called SHAREDCare in enhancing follow-up care for lung cancer survivors. The approach involves patients working with a navigator to identify their distress and social needs, followed by the development of a personalized care plan. The study includes qualitative assessments through interviews and quantitative measures to evaluate the acceptability and feasibility of the intervention. Patients will receive follow-up calls to ensure their needs are being met and to track any referrals made as a result of the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with stage I to IV lung cancer within the last two years.
Not a fit: Patients who do not have a confirmed diagnosis of lung cancer or those who are unable to understand and participate in the intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of follow-up care for lung cancer survivors, addressing their specific needs more effectively.
How similar studies have performed: Other studies have shown promise in using personalized care plans and navigators to improve patient outcomes, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed study disease. A pathology report should be referenced/available (stages I-IV lung cancer) * Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document * ≥ 18 years of age * Within two years of lung cancer diagnosis * Able to understand, read and write English Exclusion Criteria: Does not meet the above inclusion criteria
Where this trial is running
Winston-Salem, North Carolina
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AH-WFBCCC) — Winston-Salem, North Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Sarah Birken, PhD
- Email: sbirken@wakehealth.edu
- Phone: 919-357-2662
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.